Friday 8-1-2014 Amarantus Biosci Inc (AMBS) $AMBS
Post# of 64074
Posted On: 08/02/2014 10:03:27 AM
Friday 8-1-2014 Amarantus Biosci Inc (AMBS) $AMBS opened at 0.0948 hitting the high price of 0.1249 and a day low of 0.0875 with a total volume of 62,341,801. AMBS had a previous close of 0.1099 and has been seeing an average volume of 17,333,086.
Overall Average: 8% Sell
AMBS Stock Message Board http://investorshangout.com/search?q=AMBS&...mp;yt0=Go!
Cerora, Inc. Announces Second Close in Seed Round of Financing
ACCESSWIRE - Fri Aug 01, 10:15AM CDT
Supports Proprietary 'Near the Field' Objective Concussion Evaluation Technology
Amarantus Announces Positive Top-Line Interim Clinical Data for Alzheimer's Blood Diagnostic LymPro Test(R)
GlobeNewswire - Fri Aug 01, 8:25AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive interim clinical performance data for the Company's proprietary cell cycle dysregulation diagnostic blood assay LymPro Test(R), currently under development for Alzheimer's disease diagnosis. In an interim analysis of 44 subjects (34 healthy controls and 10 Alzheimer's patients) from LP-002, a projected 72 patient clinical performance study, the Company announced it achieved replication of the two earlier peer reviewed publications, the primary objective of the study.
Amarantus Acquires Exclusive Option to License Alzheimer's Therapeutic IP of Dr. Thomas Arendt From University of Leipzig
GlobeNewswire - Fri Aug 01, 7:41AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has acquired an exclusive option to license the intellectual property surrounding the therapeutic concepts of Dr. Thomas Arendt from the University of Leipzig that were presented at the 3 Alzheimer's focused Coalition for Concussion Treatment Summit. Under the terms of the agreement, the Company and the University of Leipzig will have 12 months to negotiate a definitive license agreement, and the Company will work with Dr. Arendt to establish a Sponsored Research Agreement to outline the advancement of the therapeutic strategies into human clinical development.
The 3rd Alzheimer's-Focused #C4CT Concussion Summit Convenes Today at the United Nations
GlobeNewswire - Thu Jul 31, 9:48AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, will be hosting the 3 Alzheimer's-Focused #C4CT Summit powered by MDM Worldwide at the United Nations today.
Registration for the 3rd Alzheimer's-Focused #C4CT Summit Has Closed Due to Overwhelming Interest
GlobeNewswire - Wed Jul 30, 7:06AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced that due to overwhelming registration for the upcoming #C4CT Summit to be held at the United Nations on July 31, 2014, the Coalition for Concussion Treatment is reluctantly unable to accept any new registrants. This summit will be the largest to date with hundreds of confirmed guests including doctors and medical researchers specializing in the treatment of neurodegenerative diseases, policy makers, international ambassadors, athletes and victims of traumatic brain injury (TBI). The summit will cover Alzheimer's disease and other neurodegenerative diseases and the emerging link between traumatic brain injury and neurological conditions.
Amarantus Amends LymPro LP-002 Clinical Protocol to Report Interim Data at #C4CT Presentation
GlobeNewswire - Wed Jul 30, 7:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has amended the clinical protocol for its LP-002 Alzheimer's disease bridging diagnostic study of LymPro in order to perform an interim analysis of 44 subjects recruited from a single clinical site, from an originally planned 72 subjects across 4 clinical sites. The Company intends to report full results upon completion of study enrollment from the three additional clinical sites in the 3 quarter. The Company remains on track to achieve its strategic objectives for LymPro in the 2 half of 2014.
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/djdwhf/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Eli Lilly and Company - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Avineuro Pharmaceuticals, Inc. - Novartis AG - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Pfizer Inc. - Suven Life Sciences Ltd. - Mithridion, Inc. - CoMentis, Inc. - Upsher-Smith Laboratories, Inc. - Siena Biotech S.p.A. - Dart NeuroScience LLC - Intra-Cellular Therapies, Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - SK Biopharmaceuticals Co., Ltd. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/djdwhf/cognitive
Sidney Rice and Ben Utecht Talk to NFL Network's Andrea Kremer and ESPN's Andrew Brandt at Upcoming #C4CT Concussion Awareness Summit at the United Nations
GlobeNewswire - Mon Jul 28, 2:16PM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, are pleased to provide an update surrounding the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY.
Amarantus Appoints Donald D. Huffman to Board of Directors
GlobeNewswire - Mon Jul 28, 7:41AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced the appointment of Donald D. Huffman to the Company's Board of Directors, where he will chair the newly-formed audit committee. Mr. Huffman brings over 20 years of biopharmaceutical industry experience in various financial and audit roles, with specific expertise in mergers and acquisitions.
Amarantus and BSI Announce Dr. Thomas Arendt as Presenter at 3rd Alzheimer's Focused #C4CT Concussion Awareness Summit at United Nations
GlobeNewswire - Wed Jul 23, 10:34AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced a presentation by Dr. Thomas Arendt, Professor at University of Leipzig, at the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY. Dr. Arendt will summarize his scientific hypotheses regarding the evolutional context of Alzheimer's disease, and an emerging therapeutic target in a 30 minute presentation in the afternoon session.
Amarantus and BSI Proudly Announce BIO CEO & President Jim Greenwood as Panelist for 3rd Alzheimer's Focused #C4CT Concussion Awareness Summit at United Nations
GlobeNewswire - Tue Jul 22, 2:47PM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, are proud to announce the Honorable Jim Greenwood, President & CEO of the Biotechnology Industry Organization (BIO), as a panelist for the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014, at the United Nations in New York City, NY.
Amarantus Discusses New Independent Peer-Reviewed Research Papers on MANF
GlobeNewswire - Fri Jul 18, 6:49AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has updated its MANF publications list with 8 previously undisclosed independent peer-reviewed research papers. The scientific articles include several Chinese publications as well as new publications that have been released since the beginning of 2014.
Amarantus BioScience Holdings, Inc. - "Understanding Data Presented at AAIC and Why Amarantus is Well Positioned Heading into #C4CT"
ACCESSWIRE - Thu Jul 17, 1:00PM CDT
New York, NY / July 17, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus and BSI Announce Continued Support of One Mind at the 3rd #C4CT Concussion Awareness Summit at the United Nations
GlobeNewswire - Thu Jul 17, 7:17AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, andAmarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, are pleased to announce their continued support of One Mind at the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY.
Amarantus Announces Positive Clinical Performance and 7-Year Longitudinal Data Poster Presentations for LymPro Test (R) at AAIC 2014
GlobeNewswire - Tue Jul 15, 10:34AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive clinical performance data for Version 2 of the Company's proprietary cell cycle dysregulation diagnostic blood assay LymPro Test(R), currently under development for Alzheimer's disease diagnosis. The LymPro Test clinical data package assessed was produced in 2008 at Provista Life Sciences. The 7-year longitudinal patient record clinical progression assessment data was conducted by Dr. Marwan Sabbagh at the Banner Sun Health Research institute who originally enrolled the 44 patients involved in the Provista clinical trial, and analyzed by Dr. Louis Kirby, the Company's Chief Medical Officer. LymPro differentially diagnosed Alzheimer's disease versus age-matched other dementias and cognitively intact controls in statistically significant manner. The poster presentations are available online at http://ir.stockpr.com/amarantus/scientific-publications.
Amarantus Announces Positive Analytical Performance Data Poster Presentation for LymPro Test (R) at AAIC 2014
GlobeNewswire - Mon Jul 14, 7:58AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive analytical performance data for the Company's proprietary cell cycle dysregulation diagnostic blood assay LymPro Test(R), currently under development for Alzheimer's disease diagnosis. The analytical data package, produced at the Company's contract laboratory BD Biosciences, provides the basis for reproducible clinical performance assessment of LymPro Test(R). The Company has performance univariate and multivariate analytical data analyses in an Alzheimer's population vs. a non-Alzheimer's population (cognitively intact, Parkinson's dementia and vascular dementia) to assess clinical performance. The Company will present pilot clinical performance data, and an up-to 6 year longitudinal assessment of the patients' clinical diagnosis change over time, in two complementary poster presentations on Tuesday July 15, 2014 at 11:45am local at AAIC 2014 in Copenhagen, Denmark (Poster position 117 and 118).
Amarantus BioScience Holdings "AAIC 2014: Understanding the Data Being Presented - LymPro Test(r) Version 2"
ACCESSWIRE - Wed Jul 09, 3:46PM CDT
New York, NY / ACCESSWIRE / July 9, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus' CEO to Host Twitter Chat on Thursday, July 10, 2014 at 4pm EDT
GlobeNewswire - Mon Jul 07, 3:25PM CDT
Amarantus BioScience Holdings, Inc. (OTCBB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO will host and participate in a Twitter chat on Thursday, July 10, 2014 from 4-4:30pm EDT via his Twitter handle @G_Commish.
Amarantus Announces Three Data Presentations Related to the Company's LymPro Diagnostic Test at the Alzheimer's Association International Conference (AAIC)
GlobeNewswire - Mon Jul 07, 7:30AM CDT
Amarantus BioScience Holdings, (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that analytical performance, clinical performance and 6-year longitudinal data related to the Company's LymPro Test(R) will be presented at the Alzheimer's Association International Conference (AAIC), held at the Bella Center in Copenhagen, Denmark, July 12-17, 2014.
Overall Average: 8% Sell
AMBS Stock Message Board http://investorshangout.com/search?q=AMBS&...mp;yt0=Go!
Cerora, Inc. Announces Second Close in Seed Round of Financing
ACCESSWIRE - Fri Aug 01, 10:15AM CDT
Supports Proprietary 'Near the Field' Objective Concussion Evaluation Technology
Amarantus Announces Positive Top-Line Interim Clinical Data for Alzheimer's Blood Diagnostic LymPro Test(R)
GlobeNewswire - Fri Aug 01, 8:25AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive interim clinical performance data for the Company's proprietary cell cycle dysregulation diagnostic blood assay LymPro Test(R), currently under development for Alzheimer's disease diagnosis. In an interim analysis of 44 subjects (34 healthy controls and 10 Alzheimer's patients) from LP-002, a projected 72 patient clinical performance study, the Company announced it achieved replication of the two earlier peer reviewed publications, the primary objective of the study.
Amarantus Acquires Exclusive Option to License Alzheimer's Therapeutic IP of Dr. Thomas Arendt From University of Leipzig
GlobeNewswire - Fri Aug 01, 7:41AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has acquired an exclusive option to license the intellectual property surrounding the therapeutic concepts of Dr. Thomas Arendt from the University of Leipzig that were presented at the 3 Alzheimer's focused Coalition for Concussion Treatment Summit. Under the terms of the agreement, the Company and the University of Leipzig will have 12 months to negotiate a definitive license agreement, and the Company will work with Dr. Arendt to establish a Sponsored Research Agreement to outline the advancement of the therapeutic strategies into human clinical development.
The 3rd Alzheimer's-Focused #C4CT Concussion Summit Convenes Today at the United Nations
GlobeNewswire - Thu Jul 31, 9:48AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, will be hosting the 3 Alzheimer's-Focused #C4CT Summit powered by MDM Worldwide at the United Nations today.
Registration for the 3rd Alzheimer's-Focused #C4CT Summit Has Closed Due to Overwhelming Interest
GlobeNewswire - Wed Jul 30, 7:06AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced that due to overwhelming registration for the upcoming #C4CT Summit to be held at the United Nations on July 31, 2014, the Coalition for Concussion Treatment is reluctantly unable to accept any new registrants. This summit will be the largest to date with hundreds of confirmed guests including doctors and medical researchers specializing in the treatment of neurodegenerative diseases, policy makers, international ambassadors, athletes and victims of traumatic brain injury (TBI). The summit will cover Alzheimer's disease and other neurodegenerative diseases and the emerging link between traumatic brain injury and neurological conditions.
Amarantus Amends LymPro LP-002 Clinical Protocol to Report Interim Data at #C4CT Presentation
GlobeNewswire - Wed Jul 30, 7:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has amended the clinical protocol for its LP-002 Alzheimer's disease bridging diagnostic study of LymPro in order to perform an interim analysis of 44 subjects recruited from a single clinical site, from an originally planned 72 subjects across 4 clinical sites. The Company intends to report full results upon completion of study enrollment from the three additional clinical sites in the 3 quarter. The Company remains on track to achieve its strategic objectives for LymPro in the 2 half of 2014.
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/djdwhf/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Eli Lilly and Company - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Avineuro Pharmaceuticals, Inc. - Novartis AG - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Pfizer Inc. - Suven Life Sciences Ltd. - Mithridion, Inc. - CoMentis, Inc. - Upsher-Smith Laboratories, Inc. - Siena Biotech S.p.A. - Dart NeuroScience LLC - Intra-Cellular Therapies, Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - SK Biopharmaceuticals Co., Ltd. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/djdwhf/cognitive
Sidney Rice and Ben Utecht Talk to NFL Network's Andrea Kremer and ESPN's Andrew Brandt at Upcoming #C4CT Concussion Awareness Summit at the United Nations
GlobeNewswire - Mon Jul 28, 2:16PM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, are pleased to provide an update surrounding the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY.
Amarantus Appoints Donald D. Huffman to Board of Directors
GlobeNewswire - Mon Jul 28, 7:41AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced the appointment of Donald D. Huffman to the Company's Board of Directors, where he will chair the newly-formed audit committee. Mr. Huffman brings over 20 years of biopharmaceutical industry experience in various financial and audit roles, with specific expertise in mergers and acquisitions.
Amarantus and BSI Announce Dr. Thomas Arendt as Presenter at 3rd Alzheimer's Focused #C4CT Concussion Awareness Summit at United Nations
GlobeNewswire - Wed Jul 23, 10:34AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced a presentation by Dr. Thomas Arendt, Professor at University of Leipzig, at the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY. Dr. Arendt will summarize his scientific hypotheses regarding the evolutional context of Alzheimer's disease, and an emerging therapeutic target in a 30 minute presentation in the afternoon session.
Amarantus and BSI Proudly Announce BIO CEO & President Jim Greenwood as Panelist for 3rd Alzheimer's Focused #C4CT Concussion Awareness Summit at United Nations
GlobeNewswire - Tue Jul 22, 2:47PM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, are proud to announce the Honorable Jim Greenwood, President & CEO of the Biotechnology Industry Organization (BIO), as a panelist for the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014, at the United Nations in New York City, NY.
Amarantus Discusses New Independent Peer-Reviewed Research Papers on MANF
GlobeNewswire - Fri Jul 18, 6:49AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has updated its MANF publications list with 8 previously undisclosed independent peer-reviewed research papers. The scientific articles include several Chinese publications as well as new publications that have been released since the beginning of 2014.
Amarantus BioScience Holdings, Inc. - "Understanding Data Presented at AAIC and Why Amarantus is Well Positioned Heading into #C4CT"
ACCESSWIRE - Thu Jul 17, 1:00PM CDT
New York, NY / July 17, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus and BSI Announce Continued Support of One Mind at the 3rd #C4CT Concussion Awareness Summit at the United Nations
GlobeNewswire - Thu Jul 17, 7:17AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, andAmarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, are pleased to announce their continued support of One Mind at the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY.
Amarantus Announces Positive Clinical Performance and 7-Year Longitudinal Data Poster Presentations for LymPro Test (R) at AAIC 2014
GlobeNewswire - Tue Jul 15, 10:34AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive clinical performance data for Version 2 of the Company's proprietary cell cycle dysregulation diagnostic blood assay LymPro Test(R), currently under development for Alzheimer's disease diagnosis. The LymPro Test clinical data package assessed was produced in 2008 at Provista Life Sciences. The 7-year longitudinal patient record clinical progression assessment data was conducted by Dr. Marwan Sabbagh at the Banner Sun Health Research institute who originally enrolled the 44 patients involved in the Provista clinical trial, and analyzed by Dr. Louis Kirby, the Company's Chief Medical Officer. LymPro differentially diagnosed Alzheimer's disease versus age-matched other dementias and cognitively intact controls in statistically significant manner. The poster presentations are available online at http://ir.stockpr.com/amarantus/scientific-publications.
Amarantus Announces Positive Analytical Performance Data Poster Presentation for LymPro Test (R) at AAIC 2014
GlobeNewswire - Mon Jul 14, 7:58AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive analytical performance data for the Company's proprietary cell cycle dysregulation diagnostic blood assay LymPro Test(R), currently under development for Alzheimer's disease diagnosis. The analytical data package, produced at the Company's contract laboratory BD Biosciences, provides the basis for reproducible clinical performance assessment of LymPro Test(R). The Company has performance univariate and multivariate analytical data analyses in an Alzheimer's population vs. a non-Alzheimer's population (cognitively intact, Parkinson's dementia and vascular dementia) to assess clinical performance. The Company will present pilot clinical performance data, and an up-to 6 year longitudinal assessment of the patients' clinical diagnosis change over time, in two complementary poster presentations on Tuesday July 15, 2014 at 11:45am local at AAIC 2014 in Copenhagen, Denmark (Poster position 117 and 118).
Amarantus BioScience Holdings "AAIC 2014: Understanding the Data Being Presented - LymPro Test(r) Version 2"
ACCESSWIRE - Wed Jul 09, 3:46PM CDT
New York, NY / ACCESSWIRE / July 9, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus' CEO to Host Twitter Chat on Thursday, July 10, 2014 at 4pm EDT
GlobeNewswire - Mon Jul 07, 3:25PM CDT
Amarantus BioScience Holdings, Inc. (OTCBB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO will host and participate in a Twitter chat on Thursday, July 10, 2014 from 4-4:30pm EDT via his Twitter handle @G_Commish.
Amarantus Announces Three Data Presentations Related to the Company's LymPro Diagnostic Test at the Alzheimer's Association International Conference (AAIC)
GlobeNewswire - Mon Jul 07, 7:30AM CDT
Amarantus BioScience Holdings, (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that analytical performance, clinical performance and 6-year longitudinal data related to the Company's LymPro Test(R) will be presented at the Alzheimer's Association International Conference (AAIC), held at the Bella Center in Copenhagen, Denmark, July 12-17, 2014.
(0)
(0)Scroll down for more posts ▼